Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kanta Subbarao

Showing results (211-220 of 300) with videos related to

Pageof 30
Sort By:
The Journal of Infectious Diseases|March 8, 2014
A live attenuated influenza A(H5N1) vaccine induces long-term immunity in the absence of a primary antibody responseKawsar R Talaat, Catherine J Luke, Surender Khurana, et al.
Mbio|December 10, 2025
Antibody responses following COVID-19 vaccination and breakthrough infections in naïve and convalescent individuals suggest imprinting to the ancestral strain of SARS-CoV-2Siddhartha Mahanty, Emily M Eriksson, Peta Edler, et al.
Trials|July 17, 2024
Bringing optimised COVID-19 vaccine schedules to immunocompromised populations (BOOST-IC): study protocol for an adaptive randomised controlled clinical trialDavid W J Griffin, Michael Dymock, Germaine Wong, et al.
Vaccine|June 23, 2009
Evaluation of two live attenuated cold-adapted H5N1 influenza virus vaccines in healthy adultsRuth A Karron, Kawsar Talaat, Catherine Luke, et al.
Plos Medicine|May 31, 2007
Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenzaCameron P Simmons, Nadia L Bernasconi, Amorsolo L Suguitan, et al.
Influenza and Other Respiratory Viruses|March 16, 2012
An open-label phase I trial of a live attenuated H2N2 influenza virus vaccine in healthy adultsKawsar R Talaat, Ruth A Karron, Philana H Liang, et al.
Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases|June 22, 2018
Safety, immunogenicity and protection of A(H3N2) live attenuated influenza vaccines containing wild-type nucleoprotein in a ferret modelDaniil A Korenkov, Karen L Laurie, Patrick C Reading, et al.
The Journal of Clinical Investigation|April 15, 2010
Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccineDavide Corti, Amorsolo L Suguitan, Debora Pinna, et al.
The Journal of Infectious Diseases|April 4, 2015
High-Affinity H7 Head and Stalk Domain-Specific Antibody Responses to an Inactivated Influenza H7N7 Vaccine After Priming With Live Attenuated Influenza VaccineJessica L Halliley, Surender Khurana, Florian Krammer, et al.
Open Forum Infectious Diseases|July 16, 2016
Correlates of Immunity to Influenza as Determined by Challenge of Children with Live, Attenuated Influenza VaccinePeter F Wright, Anne G Hoen, Natalia A Ilyushina, et al.
Pageof 30

Showing results (211-220 of 300) with videos related to

Sort By:
Pageof 30
The Journal of Infectious Diseases|March 8, 2014
A live attenuated influenza A(H5N1) vaccine induces long-term immunity in the absence of a primary antibody responseKawsar R Talaat, Catherine J Luke, Surender Khurana, et al.
Mbio|December 10, 2025
Antibody responses following COVID-19 vaccination and breakthrough infections in naïve and convalescent individuals suggest imprinting to the ancestral strain of SARS-CoV-2Siddhartha Mahanty, Emily M Eriksson, Peta Edler, et al.
Trials|July 17, 2024
Bringing optimised COVID-19 vaccine schedules to immunocompromised populations (BOOST-IC): study protocol for an adaptive randomised controlled clinical trialDavid W J Griffin, Michael Dymock, Germaine Wong, et al.
Vaccine|June 23, 2009
Evaluation of two live attenuated cold-adapted H5N1 influenza virus vaccines in healthy adultsRuth A Karron, Kawsar Talaat, Catherine Luke, et al.
Plos Medicine|May 31, 2007
Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenzaCameron P Simmons, Nadia L Bernasconi, Amorsolo L Suguitan, et al.
Influenza and Other Respiratory Viruses|March 16, 2012
An open-label phase I trial of a live attenuated H2N2 influenza virus vaccine in healthy adultsKawsar R Talaat, Ruth A Karron, Philana H Liang, et al.
Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases|June 22, 2018
Safety, immunogenicity and protection of A(H3N2) live attenuated influenza vaccines containing wild-type nucleoprotein in a ferret modelDaniil A Korenkov, Karen L Laurie, Patrick C Reading, et al.
The Journal of Clinical Investigation|April 15, 2010
Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccineDavide Corti, Amorsolo L Suguitan, Debora Pinna, et al.
The Journal of Infectious Diseases|April 4, 2015
High-Affinity H7 Head and Stalk Domain-Specific Antibody Responses to an Inactivated Influenza H7N7 Vaccine After Priming With Live Attenuated Influenza VaccineJessica L Halliley, Surender Khurana, Florian Krammer, et al.
Open Forum Infectious Diseases|July 16, 2016
Correlates of Immunity to Influenza as Determined by Challenge of Children with Live, Attenuated Influenza VaccinePeter F Wright, Anne G Hoen, Natalia A Ilyushina, et al.
Pageof 30